You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

~ Buy the VYZULTA (latanoprostene bunod) Drug Profile, 2024 PDF Report in the Report Store ~

VYZULTA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Vyzulta patents expire, and when can generic versions of Vyzulta launch?

Vyzulta is a drug marketed by Bausch And Lomb and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-three patent family members in thirty-eight countries.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this compound. Additional details are available on the latanoprostene bunod profile page.

DrugPatentWatch® Generic Entry Outlook for Vyzulta

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 21, 2029. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VYZULTA?
  • What are the global sales for VYZULTA?
  • What is Average Wholesale Price for VYZULTA?
Summary for VYZULTA
International Patents:53
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 23
Clinical Trials: 2
Patent Applications: 45
Drug Prices: Drug price information for VYZULTA
What excipients (inactive ingredients) are in VYZULTA?VYZULTA excipients list
DailyMed Link:VYZULTA at DailyMed
Drug patent expirations by year for VYZULTA
Drug Prices for VYZULTA

See drug prices for VYZULTA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VYZULTA
Generic Entry Date for VYZULTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VYZULTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Icahn School of Medicine at Mount SinaiPhase 4
University of California, San DiegoN/A
Bausch & Lomb IncorporatedN/A

See all VYZULTA clinical trials

Paragraph IV (Patent) Challenges for VYZULTA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VYZULTA Ophthalmic Solution latanoprostene bunod 0.024% 207795 1 2022-03-31

US Patents and Regulatory Information for VYZULTA

VYZULTA is protected by four US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VYZULTA is ⤷  Subscribe.

This potential generic entry date is based on patent 8,058,467.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VYZULTA

Prostaglandin derivatives
Patent Number: 7,273,946
Patent Expiration: ⤷  Subscribe
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Prostaglandin derivatives
Patent Number: 7,629,345
Patent Expiration: ⤷  Subscribe
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Prostaglandin derivatives
Patent Number: 7,910,767
Patent Expiration: ⤷  Subscribe
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Prostaglandin derivatives
Patent Number: 8,058,467
Patent Expiration: ⤷  Subscribe
Patented Use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes 8,058,467 ⤷  Subscribe Y ⤷  Subscribe
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes 7,910,767 ⤷  Subscribe Y Y ⤷  Subscribe
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes 7,629,345 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VYZULTA

When does loss-of-exclusivity occur for VYZULTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Intellectual Property Organization (OAPI)

Patent: 356
Patent: Prostaglandin nitrooxyderivatives.
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VYZULTA around the world.

Country Patent Number Title Estimated Expiration
South Korea 100850133 ⤷  Subscribe
Israel 176416 תולדות פרוסטגלנדין ניטרואוקסי, תכשירים רוקחיים המכילים אותן, והשימוש בהן להכנת התרופה לטיפול בגלוקומה או לחץ תוך-עיני (Prostaglandin nitrooxy derivatives, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for treating glaucoma or ocular hypertension) ⤷  Subscribe
Hong Kong 1096084 PROSTAGLANDIN NITROOXYDERIVATIVES ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.